Aberdeen Group plc Has $14.18 Million Stock Holdings in Fulcrum Therapeutics, Inc. $FULC

Aberdeen Group plc raised its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 809.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,254,027 shares of the company’s stock after buying an additional 1,116,066 shares during the quarter. Aberdeen Group plc owned 2.32% of Fulcrum Therapeutics worth $14,183,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. increased its position in Fulcrum Therapeutics by 53.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company’s stock worth $31,572,000 after buying an additional 1,589,000 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Fulcrum Therapeutics during the second quarter worth $9,207,000. Invesco Ltd. increased its position in Fulcrum Therapeutics by 448.4% during the second quarter. Invesco Ltd. now owns 470,333 shares of the company’s stock worth $3,236,000 after buying an additional 384,566 shares during the last quarter. Nantahala Capital Management LLC increased its position in Fulcrum Therapeutics by 8.9% during the third quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after buying an additional 382,485 shares during the last quarter. Finally, Boothbay Fund Management LLC lifted its stake in shares of Fulcrum Therapeutics by 104.2% in the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock worth $6,241,000 after buying an additional 346,136 shares during the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Analyst Upgrades and Downgrades

FULC has been the subject of a number of analyst reports. Bank of America boosted their price objective on shares of Fulcrum Therapeutics from $6.00 to $7.00 and gave the stock an “underperform” rating in a research note on Tuesday, December 9th. JPMorgan Chase & Co. initiated coverage on shares of Fulcrum Therapeutics in a research note on Monday, January 12th. They issued an “overweight” rating and a $20.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, January 22nd. Truist Financial set a $17.00 price objective on shares of Fulcrum Therapeutics in a research note on Tuesday, February 24th. Finally, Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Fulcrum Therapeutics Price Performance

NASDAQ:FULC opened at $7.83 on Wednesday. The stock has a market cap of $521.48 million, a P/E ratio of -6.64 and a beta of 3.27. Fulcrum Therapeutics, Inc. has a one year low of $2.49 and a one year high of $15.74. The company has a fifty day moving average price of $8.77 and a 200 day moving average price of $9.65.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). As a group, equities research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.